Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 11/2017

01-11-2017 | Original paper

Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry

Authors: Marshall K. Tulloch-Reid, Norma McFarlane-Anderson, Franklyn I. Bennett, William D. Aiken, Maria D. Jackson

Published in: Cancer Causes & Control | Issue 11/2017

Login to get access

Abstract

Purpose

To investigate the association between serum cholesterol and prostate cancer and whether any effect may be mediated through inflammatory markers.

Methods

Data from a case–control study of 40–80 years old Jamaican male patients (229 cases; 252 controls) were used. Cases had incident histologically-confirmed prostate cancer and controls were men with normal digital rectal examination and prostate-specific antigen (PSA) < 4 μg/L or free: total PSA > 0.15 obtained from the same clinic. Total and HDL cholesterol, interleukin-6 (IL-6), and C-reactive protein (CRP) were measured from a non-fasting sample. Multivariable logistic regression models were used to evaluate the associations between these factors and prostate cancer, adjusting for age, body mass index, waist circumference, family history of prostate cancer, diabetes, hypertension, use of cholesterol-lowering drugs, and smoking.

Results

Total cholesterol [Mean (cases, 4.71 ± 1.07; controls, 4.64 ± 1.07 mmol/L)], CRP [median (cases, 2.11; controls, 2.09 µg/ml)], and IL-6: [median (cases, 3.34; controls, 3.24 pg/ml)] did not differ by PCA status. Higher total cholesterol was associated with an increased risk of low-grade disease after adjusting for potential confounders [multivariable-adjusted OR (95% CI): tertile 2: 3.32(1.66, 6.45), tertile 3: 2.14(1.07, 4.32)]. Total cholesterol was unrelated to overall prostate cancer or high-grade disease. There was no significant association between HDL cholesterol or any of the inflammatory markers with prostate cancer.

Conclusions

Increasing total cholesterol but not inflammatory markers were associated with low-grade prostate cancer in Caribbean men.
Literature
1.
Fitzmaurice C, Dicker D, Pain A et al (2015) The global burden of cancer 2013. JAMA Oncol 1:505–527CrossRefPubMed
2.
Gibson TN, Hanchard B, Waugh N, McNaughton D (2010) Age-specific incidence of cancer in Kingston and St. Andrew, Jamaica, 2003–2007. West Indian Med J 59:456–464PubMed
3.
4.
5.
6.
Simons K, Vaz WL (2004) Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct 33:269–295CrossRefPubMed
7.
8.
Schaffner CP (1981) Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res 75:279–324
9.
Solomon KR, Freeman MR (2011) The complex interplay between cholesterol and prostate malignancy. Urologic Clin N Am 38:243–259CrossRef
10.
Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR (2002) Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62:2227–2231PubMed
11.
Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB (2012) Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE 7:e30062CrossRefPubMedPubMedCentral
12.
Sun Y, Sukumaran P, Varma A, Derry S, Sahmoun AE, Singh BB (2014) Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. Biochem Biophys Acta 1843:1839–1850CrossRefPubMedPubMedCentral
13.
14.
von Eckardstein A, Hersberger M, Rohrer L (2005) Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutri Metab Care 8:147–152CrossRef
15.
YuPeng L, YuXue Z, PengFei L et al (2015) Cholesterol levels in blood and the risk of prostate cancer: a meta-analysis of 14 prospective studies. Cancer Epidemiol Biomarkers Prev 24:1086–1093CrossRefPubMed
16.
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444CrossRefPubMed
17.
18.
19.
Guthrie GJ, Roxburgh CS, Horgan PG, McMillan DC (2013) Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 39:89–96CrossRefPubMed
20.
Malinowska K, Neuwirt H, Cavarretta IT et al (2009) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16:155–169CrossRefPubMed
21.
Jackson MD, Walker SP, Simpson-Smith CM et al (2012) Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. Cancer Causes Control 23:23–33CrossRefPubMed
22.
Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64CrossRefPubMed
23.
Knekt P, Reunanen A, Aromaa A, Heliovaara M, Hakulinen T, Hakama M (1988) Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol 41:519–530CrossRefPubMed
24.
Platz EA, Till C, Goodman PJ et al (2009) Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 18:2807–2813CrossRefPubMedPubMedCentral
25.
Kitahara CM, Berrington de Gonzalez A, Freedman ND et al (2011) Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 29:1592–1598CrossRefPubMedPubMedCentral
26.
Hiatt RA, Fireman BH (1986) Serum cholesterol and the incidence of cancer in a large cohort. J Chronic Dis 39:861–870CrossRefPubMed
27.
Allott EH, Howard LE, Aronson WJ et al (2016) Racial differences in the association between preoperative serum cholesterol and prostate cancer recurrence: results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev 25:547–554CrossRefPubMedPubMedCentral
28.
Strohmaier S, Edlinger M, Manjer J et al (2013) Total serum cholesterol and cancer incidence in the metabolic syndrome and cancer project (Me-Can). PLoS ONE 8:e54242CrossRefPubMedPubMedCentral
29.
Kritchevsky SB, Wilcosky TC, Morris DL, Truong KN, Tyroler HA (1991) Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Can Res 51:3198–3203
30.
31.
Ahn J, Lim U, Weinstein SJ et al (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18:2814–2821CrossRefPubMedPubMedCentral
32.
33.
Farwell WR, D’Avolio LW, Scranton RE, Lawler EV, Gaziano JM (2011) Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 103:885–892CrossRefPubMedPubMedCentral
34.
Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508–519CrossRefPubMed
35.
36.
Cho KJ, Hill MM, Chigurupati S, Du G, Parton RG, Hancock JF (2011) Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. Mol Cell Biol 31:1110–1120CrossRefPubMedPubMedCentral
37.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT (2013) High-density lipoprotein and prostate cancer: an overview. J Epidemiol 23:313–319CrossRefPubMed
38.
Van Hemelrijck M, Walldius G, Jungner I et al (2011) Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control 22:1011–1019CrossRefPubMed
39.
His M, Zelek L, Deschasaux M et al (2014) Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol 29:119–132CrossRefPubMed
40.
Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC (2005) Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103:1186–1194CrossRefPubMed
41.
Eroglu M, Yilmaz N, Yalcinkaya S, Ay N, Aydin O, Sezer C (2013) Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients. Kaohsiung J Med Sci 29:368–373CrossRefPubMed
42.
Platz EA, De Marzo AM, Erlinger TP et al (2004) No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate 59:393–400CrossRefPubMed
43.
Stark JR, Li H, Kraft P et al (2009) Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 124:2683–2689CrossRefPubMedPubMedCentral
44.
Van Hemelrijck M, Jungner I, Walldius G et al (2011) Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer 129:1485–1492CrossRefPubMed
45.
Arthur R, Moller H, Garmo H et al (2016) Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Med 5:1307–1318CrossRefPubMedPubMedCentral
Metadata
Title
Effects of cholesterol, C-reactive protein, and interleukin-6 on prostate cancer risk in a population of African ancestry
Authors
Marshall K. Tulloch-Reid
Norma McFarlane-Anderson
Franklyn I. Bennett
William D. Aiken
Maria D. Jackson
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 11/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0945-4

Other articles of this Issue 11/2017

Cancer Causes & Control 11/2017 Go to the issue

Original Paper

Reliance on medicinal plant therapy among cancer patients in Jamaica

Original paper

Prevalence of oral HPV infection among healthy individuals and head and neck cancer cases in the French West Indies

Original paper

Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008–2013 from a population-based cancer registry

Original paper

The prostate cancer screening clinic in the Bahamas: a model for low- and middle-income countries

Original paper

Outcomes of treatment in men with prostate cancer at the cancer centre Bahamas

Original paper

Gatekeepers’ perceptions of the quality and availability of services for breast and cervical cancer patients in the English-speaking Windward Islands: an exploratory investigation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits